Amylin's 2nd-qtr 2008 loss widens to $64.8M
The USA's Amylin Pharmaceuticals says that second-quarter 2008 product sales totaled $200.3 million versus $167.3 million in the same period last year. Lead drug, diabetes injection Byetta (exenatide), earned $177.5 million vs $152.1 million, while Symlin (pramlintide acetate) injection generated $22.8 million vs $15.2 million.
Despite higher product turnover, the San Diego-based diabetes specialist saw its net loss widen to $64.8 million, or $0.47 per share, from $45.0 million, or $0.34 per share. Revenues under collaborative agreements were $21.7 million for the quarter ended June 30, 2008, compared to $29.6 million for the same period last year.
Collaborative revenues mainly consist of cost-sharing payments from partner Eli Lilly for development expenses associated with exenatide once-weekly and Byetta. They included $15.0 million in milestones, earned upon the US drug major's launch of Byetta in the European Union.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze